PerkinElmer Acquires Dexela Limited
WALTHAM, Mass. –PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has acquired Dexela Limited, a London, UK-based provider of flat panel Complementary Metal-Oxide-Semiconductor (CMOS) X-ray detection technologies and services.
The acquisition of Dexela expands PerkinElmer’s current medical imaging portfolio in key areas including surgery, dental CT, cardiology, and mammography, as well as non-destructive testing (NDT). With the addition of the CMOS technology to the Company’s imaging portfolio, customers will now be able to choose seamlessly between two complementary X-ray detector technologies to optimize their system performance and meet their specific application needs.
Founded in 2005, Dexela develops and commercializes its CMOS technology portfolio, which includes hardware and software offerings for fast, low-dose X-ray imaging. The company’s CMOS products offer high spatial resolution frame rate and reliability, low noise and absence of image lag. The Dexela technology is designed to provide high image quality, whether detecting defects in human tissue or industrial objects and structures, through design-friendly components that can be easily incorporated into an Original Equipment Manufacturer (OEM) instrument or platform.
In addition to its CMOS X-ray detection units, Dexela technologies and services include its Dexela Mammography Workstation, the DexView Image Processing Software, its 3D Reconstruction Engine Software, and Consulting and Implementation Services
“Dexela has been a pioneer in the development of CMOS X-ray detection solutions and has achieved award-winning recognition in the imaging market for its design strengths and ease of manufacturability – which are major advantages for OEM customers,” said Brian Giambattista, President, Medical Imaging, PerkinElmer. “We look forward to expanding the reach of this promising technology into adjacent markets such as surgery, dental CT, cardiology, mammography and industrial NDT, to detect, monitor and remediate threats to human health or structural integrity.”
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) reduction or elimination of dividends on our common stock; and (22) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Dexela Limited
Based in London, Dexela is a developer of innovative technologies for fast, low-dose X-ray imaging. Formed in 2005, Dexela pioneered developments in breast tomosynthesis. In 2009, Dexela launched a family of flat panel CMOS X-ray detectors ideally suited to breast tomosynthesis and a range of other applications including mammography, fluoroscopy, dental CBCT, cardiology, angiography and bone densitometry, scientific instrumentation and non-destructive testing.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Amanda L. Connolly
Edelman (on behalf of PerkinElmer, Inc.)